Ezekiel Onigbinde
Family Medicine · Monroe, LANPI 1861879926
Payments from drug & device makers
Across 67 payments — averaging $28.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$537
- Johnson & Johnson$282
- AstraZeneca$176
- Madrigal Pharmaceuticals$164
- Pfizer$150
- Novartis$118
- plus $472 from 16 others
What the payments were for
- Food & beverage$1,898100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 10 | $537 |
| Johnson & Johnson | 13 | $282 |
| AstraZeneca | 4 | $176 |
| Madrigal Pharmaceuticals | 2 | $164 |
| Pfizer | 8 | $150 |
| Novartis | 7 | $118 |
| Vanda Pharmaceuticals Inc. | 1 | $92 |
| Shire North American Group Inc | 3 | $58 |
| Merck | 4 | $50 |
| GSK | 2 | $48 |
| Exact Sciences | 2 | $29 |
| Corium, LLC | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Portola Pharmaceuticals, LLC | 1 | $21 |
| Gilead | 1 | $21 |
| Lilly USA, LLC | 1 | $17 |
| Biofire Diagnostics, LLC | 1 | $16 |
| La Jolla Pharmaceutical Company | 1 | $15 |
| Alkermes, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Novo Nordisk | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,898 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $24,295 |
| JardianceEmpagliflozin | 16 | $21,659 |
| OzempicSemaglutide | 15 | $18,013 |
| JanuviaSitagliptin Phosphate | 19 | $13,259 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $4,765 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $974 |
| Gabapentin | 71 | $747 |
| Tizanidine Hcl | 11 | $576 |
| Atorvastatin Calcium | 92 | $371 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 13 | $277 |
| Amlodipine Besylate | 75 | $270 |
| Allopurinol | 11 | $245 |
| Lisinopril | 44 | $231 |
| Carvedilol | 20 | $215 |
| Levetiracetam | 12 | $204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia | $50 | $37,55535 claims |
| Novo NordiskOzempic | $13 | $18,01315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Monroe
- Clinton GuilloryMonroe$18.5M
- Thomas DansbyMonroe$169K
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.